Jill Henrich
General Counsel at ATARA BIOTHERAPEUTICS, INC.
Net worth: 385 171 $ as of 31/03/2024
Profile
Jill Henrich is currently the Executive VP & Head-Global Regulatory Affairs at Atara Biotherapeutics, Inc. She previously worked as the Senior Director-Regulatory Affairs at Corixa Corp., the Director-Regulatory Affairs & Quality Assurance at PDL BioPharma, Inc., the Principal at Genentech, Inc., and the Senior VP-Regulatory Affairs & Quality Assurance at OncoMed Pharmaceuticals, Inc. She also held the position of Senior VP-Regulatory Affairs & Head-US Site at Mereo BioPharma Group Plc.
Ms. Henrich obtained her undergraduate degree from the University of Connecticut.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 04/03/2024 | 555,001 ( 0.43% ) | 385 171 $ | 31/03/2024 |
Jill Henrich active positions
| Companies | Position | Start |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | General Counsel | - |
Former positions of Jill Henrich
| Companies | Position | End |
|---|---|---|
| ONCOMED PHARMACEUTICALS INC | General Counsel | 01/09/2020 |
| PDL BIOPHARMA, INC. | General Counsel | 01/01/2008 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/01/1997 |
| MEREO BIOPHARMA GROUP PLC | General Counsel | - |
Corixa Corp.
 Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | General Counsel | - |
Training of Jill Henrich
| University of Connecticut | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| MEREO BIOPHARMA GROUP PLC | Health Technology |
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Health Technology |
OncoMed Pharmaceuticals, Inc.
 OncoMed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA. | Health Technology |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
- Stock Market
- Insiders
- Jill Henrich